5-chloro-1-(4-piperidyl)indoline | 1571907-72-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-chloro-1-(4-piperidyl)indoline
• 英文别名: 5-Chloro-1-piperidin-4-yl-2,3-dihydroindole；5-chloro-1-piperidin-4-yl-2,3-dihydroindole
• CAS: 1571907-72-6
• 化学式: C₁₃H₁₇ClN₂
• 分子量: 236.744
• InChiKey: FPZYKCHWNVCFLU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-chloro-1-(4-piperidyl)indoline 在 盐酸 、 三乙胺 作用下， 以 乙醚 、 二甲基亚砜 为溶剂， 反应 7.5h， 生成
  参考文献：
  名称：

  4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: Part 2. Pyridazine-based analogs

  摘要：

  Design, synthesis, and biological evaluation of pyridazine-based, 4-bicyclic heteroaryl-piperidine derivatives as potent stearoyl-CoA desaturase-1 (SCD1) inhibitors are described. In a chronic study of selected analog (3e) in Zucker fa/fa (ZF) rat, dose-dependent decrease of body weight gain and plasma fatty acid desaturation index (DI) in both C16 and C18 are also demonstrated. The results indicate that the plasma fatty acid DI may serve as an indicator for direct target engagement and biomarker for SCD1 inhibition. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.075
• 作为产物：
  描述：

  5-氯吲哚啉 在 三乙酰氧基硼氢化钠 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 27.0h， 生成 5-chloro-1-(4-piperidyl)indoline
  参考文献：
  名称：

  4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: Part 2. Pyridazine-based analogs

  摘要：

  Design, synthesis, and biological evaluation of pyridazine-based, 4-bicyclic heteroaryl-piperidine derivatives as potent stearoyl-CoA desaturase-1 (SCD1) inhibitors are described. In a chronic study of selected analog (3e) in Zucker fa/fa (ZF) rat, dose-dependent decrease of body weight gain and plasma fatty acid desaturation index (DI) in both C16 and C18 are also demonstrated. The results indicate that the plasma fatty acid DI may serve as an indicator for direct target engagement and biomarker for SCD1 inhibition. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.075

文献信息

• OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS
  申请人：Hoffmann-La Roche Inc.

  公开号：US20210107920A1

  公开（公告）日：2021-04-15

  The invention provides new heterocyclic compounds having the general formula (Ic) wherein A, L, X, m, n and R 20 to R 23 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.